A Novel Adjuvant-based Probiotic Platform for Generating Tolerance Therapeutics
$585,350N01FY2018AINIH
Virtici, Llc, Seattle WA
Investigators
Abstract
The project is to develop a novel adjuvant-based probiotic platform to induce tolerance for the treatment of allergy.
View original record on NIH RePORTER →